Respiratory syncytial virus replication inhibitors

Details Respiratory syncytial virus replication inhibitors Respiratory syncytial virus replication inhibitors

2006-07-04

2006-07-04

Coleman, Brenda (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S253060, C514S299000, C514S300000, C514S302000, C514S303000, C514S307000, C514S312000, C514S314000, C514S322000, C544S253000, C544S254000, C544S356000, C544S363000, C546S112000, C546S115000, C546S118000, C546S122000, C546S148000, C546S153000, C546S157000, C546S167000, C546S174000, C546S175000, C546S176000, C546S199000

Reexamination Certificate

active

07071192

ABSTRACT:
The present invention concerns compounds of formula (I), prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms thereof wherein -a1=a2-a3=a4-represents a radical of formula —CH═CH—CH═CH—; —N—CH—CH═CH—; —CH═N—CH═CH—; —CH═CH—N═CH—; —CH═CH—CH═N—; wherein each hydrogen atom may optionally be substituted; Q is a radical of formulae (b-1), (b-2), (b-3), (b-4), (b-5), (b-6), (b-7) and (b-8), wherein Alk is C1-6alkanediyl; Y1is a bivalent radical of formula —NR2— or —CH(NR2R4)—; X1is NR4, S, S(═O), S(═O)2, O, CH2, C(═O), CH(═CH2), CH(OH), CH(CH3), CH(OCH3), CH(SCH3), CH(NR5aR5b), CH2—NR4or NR4—CH2; X2is a direct bond, CH2, C(═O), NR4, C1-4alkyl-NR4, NR4—C1-4alkyl, t is 2 to 5; u is 1 to 5; v is 2 or 3; and whereby each hydrogen in Alk and in (b-3), (b-4), (b-5), (b-6), (b-7) and (b-8), may optionally be replaced by R3: provided that when R3is hydroxy or C1-6alkyloxy, then R3cannot replace a hydrogen atom in the a position relative to a nitrogen atom; G is a direct bond or optionally substituted C1-10alkanediyl; R1is an optionally substituted bicyclic heterocycle; R2is hydrogen, formyl, C1-6alkylcarbonyl, Hetcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, C3-7cycloalkyl or C1-10alkyl substituted with N(R6)2and optionally with another substituent; R3is hydrogen, hydroxy, C1-6alkyl, C1-6alkyloxy, aryl C1-6alkyl or aryl C1-6alkyloxy, R4is hydrogen, C1-6alkyl or aryl C1-6alkyl; R5a, R5b, R5cand R5dare hydrogen or C1-6alkyl; or R5aand R5b, or R5cand R5dtaken together from a bivalent radical of formula —(CH2)5- wherein S is 4 or 5; R6is hydrogen, C1-4alkyl, formyl, hydroxy C1-6alkyl, C1-6alkylcarbonyl or C1-6alkyloxycarbonyl; aryl is optionally substituted phenyl; Het is pyridyl, pyrimidinyl, pyridazinyl, pyridazinyl; as respiratory syncytial virus replication inhibitors; their preparation, compositions containing them and their use as a medicine.

REFERENCES:
patent: 4634704 (1987-01-01), Janssens et al.
patent: 4695569 (1987-09-01), Janssens et al.
patent: 5597824 (1997-01-01), Norbeck et al.
patent: 0 005 318 (1979-11-01), None
patent: 0 099 139 (1984-01-01), None
patent: 0 144 101 (1985-06-01), None
patent: 0 145 037 (1985-06-01), None
patent: 0 151 824 (1985-08-01), None
patent: 0 151 826 (1985-08-01), None
patent: 0 232 937 (1987-08-01), None
patent: 0 295 742 (1988-12-01), None
patent: 0 297 661 (1989-01-01), None
patent: 0 307 014 (1989-03-01), None
patent: 0 433 898 (1991-06-01), None
patent: 0 747 363 (1996-12-01), None
patent: WO 92/01687 (1992-02-01), None
patent: WO 92/01697 (1992-02-01), None
patent: WO 98/10764 (1998-03-01), None
patent: WO 98/31363 (1998-07-01), None
patent: WO 98/55120 (1998-12-01), None
patent: WO 99/44596 (1999-09-01), None
patent: WO 00/04900 (2000-02-01), None
Akula, M. R. et al., “An Improved Synthesis of 3-Phenyl-and 3-Methoxyquinaldine,”Org. Prep. Proced. Int., 1991, 23, pp. 386-387.
Cerè, V. et al., “Catalytic Hydrogenation of Benzo[2.1.3]Oxadiazoles,”Tetrahedron, 1972, 28, 3271-3276.
Chiba, T. et al., “Inhibitory Effect of Pyridobenzazoles on Virus Replication in vitro,”Biol Pharm Bull, 1995, 18(8), 1081-1083.
Goodman and Gilman, “Biotransformation of Drugs,” inThe Pharmacological Basis of Therapeutics, 9thed., McGraw-Hill, Int. Ed. 1992, 13-15.
Greene, T. et al.,Protective Groups in Organic Synthesis, John Wiley & Sons Inc., 1991, Chapter 7.
Lindström, S. et al., “Synthesis of the Mutagenic 2-Amino-1,6-Dimethyl-Imidazo[4,5-b]Pyridine (1,6-DMIP) and Five of Its Isomers,”Heterocycles, 1994, 38(3), 529-540.
Richardson, Jr. et al. “Study of the Synthesis and Chemistry of the 5,6-Dihydroimidazo[ij]quinoline Series,”J. Org. Chem., 1960, 25, 1138-1147.
Tidwell, R. et al., “Aromatic Amidines: Comparison of Their Ability to Block Respiratory Syncytial Virus Induced Cell Fusion and to Inhibit Plasmin, Urokinase, Thrombin, and Trypsin,”J Med Chem, 1983, 26, 294-298.
Wyde et al., “CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats,”Antivirus Research, 1998, 38, 31-42.

Affiliated with

Also associated with

Rating

Respiratory syncytial virus replication inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Respiratory syncytial virus replication inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Respiratory syncytial virus replication inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3580650